Loading...
  • anticancer
  • 5-Fluorouracil (5-FU) is a classic antimetabolite anticancer drug with a chemical structure similar to endogenous intermediates or building blocks of DNA or RNA synthesis. (medscape.com)
  • 29: 515-523doi:10.1016/S0305-7372(03)00116-6 Classification of anticancer drugs-a newsystem based on therapeutic targets Enrique Espinosa, Pilar Zamora, Jaime Feliu andManuel Gonza´lez Baro´n Servicio de Oncologı´a Me´dica, Hospital La Paz, Madrid, Spain The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. (medpdffinder.com)
  • The last years have witnessed the ap- pearance of a great number of anticancer drugs, We hereby propose a new drug classification many of which cannot be included in a simple based on the kind of target. (medpdffinder.com)
  • Most classical anticancer agents have one of these mech- anism of action, and new drugs are being incorpo- rated every year (Tables 3a and 3b). (medpdffinder.com)
  • Therapy
  • The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historical controls. (clinicaltrials.gov)
  • To compare the activities (the progression-free survival, the incidence and severity of toxicities, and reversibility of toxicities) of erlotinib to that of platinum-based therapy in NSCLC. (clinicaltrials.gov)
  • However, data will be generated which will show the safety and efficacy of erlotinib in the frontline setting (alone and with historical comparison to platinum-based therapy), as well as the potential safety and activity of platinum-based therapy in the 'second-line' (post-erlotinib) setting. (clinicaltrials.gov)
  • For human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to la. (bioportfolio.com)
  • We have restricted the in- nitrosoureas, triazenes, platinum compounds and clusion of new compounds to those under clinical Non-specificDNA break: chemotherapyDNA-related proteins: chemotherapySpecificHormonal therapy, retinoidsInterferon aGene therapy Membrane receptorsExtracellular domain: MoAbIntracellular domain: small moleculesCytoplasmIntracellular pathways: small moleculesTubulin: chemotherapy * In this group, antisense therapy might also be developed in the future. (medpdffinder.com)
  • Biological
  • The maximum dose of Decitabine (20 mg/m2) is based on the results of the myelodysplastic syndrome (MDS) clinical trial that demonstrated biological and clinical efficacy at this dose (15-17). (clinicaltrials.gov)
  • combinations
  • Since confirmed interactions are sporadic and based largely on case reports, advice to avoid certain drug-CAM combinations is based on known pharmacological and in vitro properties. (medicinalplants.us)
  • portion
  • A significant portion of the product derived from plants serve either as protective agents against various pathogens (e.g., insects, fungi, or bacteria) or growth regulatory molecules (e.g., hormonelike substances that stimulate or inhibit cell division and morphogenesis). (medicinalplants.us)
  • Although
  • Although these agents are very active from a therapeutic perspective, they are also notorious for their tendency to cause carcinogenesis and mutagenesis. (medicinalplants.us)